A study released online today by the British Journal of Psychiatry shows that the clinical profile of neuroleptic malignant syndrome (NMS) is similar in 1st- v. 2nd-generation antipsychotics. Patients presenting with NMS from 2nd generation are younger, with less rigidity and a lower mortality rate.
Trollor, J. Chen, X. Chitty, K. Sachdev, P. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics, British Journal of Psychiatry, Published online May 26, 2012
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.